In recent years, research has focused on the immunoreactive components of the S. schenckii cell 14 wall that can be relevant targets for preventive and therapeutic vaccines against sporotrichosis, an 15 emergent worldwide mycosis. In previous studies, we identified a 47-kDa enolase as an 16 immunodominant antigen in mice vaccinated with purified fungal wall proteins and adjuvants. In 17 this study, the immunolocalization of this immunogen in the cell wall of S. schenckii and S. 18 brasiliensis is shown for the first time. In addition, a recombinant enolase of Sporothrix spp 19 (rSsEno) was studied with the adjuvant Montanide Pet-GelA (PGA) as a vaccine candidate. The 20 rSsEno was produced with high purity. In addition, mice immunized with rSsEno plus PGA 21 showed increased antibody titers against enolase and increased median survival time compared to 22 nonimmunized or rSsEno-immunized mice. Enolase immunization induced a predominant T-23 helper-1 (Th1) cytokine pattern in splenic cells after in vitro stimulation with rSsEno. Elevated 24 production of interferon-ɣ (IFN-ɣ) and interleukin-2 (IL-2) was observed with other cytokines 25 involved in the innate immune defense, such as TNF-alpha, IL-6, and IL-4, which are necessary 26 for antibody production. These results suggest that we should continue testing this antigen as a 27 potential vaccine candidate against sporotrichosis. 28 29 Introduction 30 Sporotrichosis is a subcutaneous mycosis of subacute or chronic evolution caused by traumatic 31 inoculation or the inhalation of spores of different species of the Sporothrix genus affecting both 32 humans and animals 1 . The disease has a universal geographical distribution, although it is endemic 33 in Latin America, including in Peru, México, Colombia, Guatemala and, especially, Brazil, where 34 in the last 20 years, it became an important zoonosis, with the cat being the main source of 35 transmission 2-4 . Species of the Sporothrix genus are thermodymorphic fungi with a saprophytic 36 life at 25 °C and a filamentous form. The parasitic form at 35-37 °C is a yeast 1,5 . The human 37 infection is acquired in two ways: traumatic inoculation through the skin with materials 38 contaminated with Sporothrix spp or inhalation. Zoonotic transmission principally occurs from 39 cats to humans 6 . 40 The genus Sporothrix is currently classified into two clades: i) the clinical clade, which includes 41 S. brasiliensis, S. globosa, S. luriei and S. schenckii sensu stricto and ii) the environmental clade, 42 composed mainly of species less pathogenic to man and animals, such as S. mexicana, S. pallida 43 and S. chilensis 7,8 . Brazil is the only country that has reported all species of the clinical clade, and 44 S. brasiliensis is the most virulent species 9,10 . This species is also the most prevalent during 45 zoonotic transmission through deep scratches and bites from infected cats 8 . In this country, though 46 sporotrichosis has been reported in most states, the disease is a neglected disease, particularly in 47 the state of Rio de Janeiro (JR), where the largest number of cases has been reported, representing 48 a serious public health problem 3 . The Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, a 49 referral center for the diagnosis and treatment of this mycosis, diagnosed over 4000 human and 50 feline sporotrichosis cases between 1998 and 2012 11 . More recently, according to data from the 51 epidemiological bulletin of 001/2018 of the sanitary vigilance service of RJ, during 2015 to 2018 52 (May), 3510 new cases were confirmed 12 , which shows a progressive increase in the incidence and 53 prevalence of this mycosis. 54 Sporotrichosis is usually controlled through the combined use of itraconazole/potassium iodide or 55 terbinafine in immunocompetent patients who exhibit the less severe clinical forms of the disease 56 (lymphocutaneous and fixed cutaneous lesions) 13,14 . However, in immunocompromised patients 57 with neoplastic diseases, transplantation or AIDS, the conventional treatment with classical 58 antifungals is generally ineffective 15,16 . The lack of a veterinary and/or human vaccine against this 59 disease has awakened interest in the identification of S. schenckii cell wall immunoreactive 60 components involved in fungal pathogenesis 17 and the induction of the immune response 18 that can 61 be used for immunoprophylaxis and immunotherapy against sporotrichosis.
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After confirming their specificity, the anti-rSsEno serum was used to detect enolase in the 124 Ss16345, Ss1099-18, Ss250 and Ss256-cell wall. Figure 4 (A, C, E and G) shows an intense and 125 significant (p<0.05) median fluorescence intensity (MFI) in yeasts treated with the anti-rSsEno 126 serum compared to yeast treated with serum from nonimmunized mice (NIS), evidencing enolase 127 on the cell surface of these strains. The MFI was higher in the cat isolate ( Fig. 4F and H) compared 128 to Ss16345 (Fig. 4B ) and Ss1099-18 ( Fig. 4D ), suggesting that this protein is expressed more on 129 the cell wall of S. brasiliensis, the more virulent species. The presence of enolase on the cell surface 130 of the studied fungi was also confirmed by transmission microscopy using the immunogold stain.
131 Figure 4 showed that enolase appears distributed along the cell wall of Ss16345, Ss1099-18, Ss250 132 and Ss256, which might facilitate its recognition by the host's immune system, although it also 133 appears, as expected, in the cellular cytoplasm of these species, since its classical function is to 134 catalyze the reversible conversion of 2-phosphoglycerate to phosphoenolpyruvate 22, 33 . 135 Antibody response 136 To assess the immunogenic potential of S. schenckii-enolase, sera from the experimental group 137 obtained seven days after the last boost was subjected to ELISA using rSsEno as an antigen. Our 138 results showed that animals immunized only with enolase stimulated high IgG specific antibody 139 production ( Fig. 5A ) compared to the PBS group. However, as expected, the specific antibody 140 production was significantly higher (p <0.05) when enolase was formulated with the PGA 141 adjuvant. We also determined the rSsEno-specific IgG1, IgG2a and IgG3 antibodies induced by 142 each formulation. Mice immunized with rSsEno100 and PGA+rSsEno100 induced higher IgG1 143 and IgG3 antibody levels against rSsEno compared to the PBS control group, but the level of both 144 subclasses was higher in the mice immunized with the PGA-adjuvanted formulation ( Fig. 5B and 145 C). The PGA+rSsEno100 formulation was the only formulation that induced the production of 146 IgG2a (Fig. 5D ).
147

Cytokine profile analysis 148
The effect of anti-enolase vaccination on the pattern of cytokines was evaluated in the supernatant 149 of splenocyte cultures from nonimmunized and immunized mice after in vitro stimulation with 150 rSSEno100. A higher production of IL-2 and IFN-ɣ from the Th1 profile, IL-4 and IL-6, which 151 are involved in the production of antibodies, and TNF-α, which is released during the innate 152 immune response (also with IL-6) in mice vaccinated with PGA+rSsEno100, was observed ( Fig.   153 6). All of these cytokines are involved in defense against S. schenckii, which is additional evidence 154 of protective immunogenicity induced by the vaccine formulation.
155
Challenge studies 156 To test whether rSsEno in the formulation with PGA adjuvant protects against systemic 157 sporotrichosis in mice, seven days after booster immunization, mice from each group were 158 challenged intravenously with 10 5 S. brasiliensis 250 yeasts, a highly virulent specie. The mortality 159 of nonimmunized mice was of 100% before 40 days postinfection, while the rSsEno-immunized 160 mice showed over 50% survival, and those immunized with the PGA-adjuvanted formulation 161 exhibited the highest percentage of survival (over 90%) at the end of the experiment (45 days 162 postinfection) ( Fig. 7) . These results clearly show that enolase may have a potential use for 163 vaccination against sporotrichosis. In this study, the enolase of S. schenckii was obtained by recombination with E. coli, and it was 171 purified and characterized. Our results showed that rSsEno was produced successfully with the 172 expected molecular weight of 47 kDa and with the secondary structure of a type α-helix at 46% 173 and a β-sheet at 12%. These values are close to values of 43% for the α-helix and 15% for the β- result. We expected that this protein would be assembled in the form of dimers, as reported for 177 yeast enolase 36-38 . However, our results indicate that the rSsEno was produced with a molecular 178 weight of 480 kDa, ten times greater than the 47 kDa monomeric unit of this protein.
179
Enolase has been described as a moonlighting protein that exhibits multiple nonglycolytic is organized in dimers and octamers and that the latter probably exist in vivo since it showed 185 enzymatic activity in vitro. Whether the complex oligomeric state of rSsEno in solution is the same 186 as its native form in S. schenckii, and its functional role in vivo, is a subject for future studies.
187
The reactivity of sera from cats with sporotrichosis against rSsEno and the lack of reactivity with 188 sera from uninfected control cats evidenced the antigenic role and probable immunogenicity of the 189 S. schenckii enolase during the infectious process in these animals. This result, in addition to the Different studies have shown that enolase on the cell surface of bacteria, fungus and parasites acts 195 as a virulence factor that facilitates the colonization and dissemination of these pathogens in the 196 host 25, 38, 41 . In this study, we show for the first time that enolase is present on the cellular surface 
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Flow cytometry
To demonstrate the enolase on the cell wall of Ss16345, Ss 1099-18, Ss250 and Ss256, 10 6 yeasts 340 were incubated for 1 h at 37ºC with anti-rSsEno serum. Serum from naïve mice was used as a 341 nonspecific binding control at a 1:50 dilution. After incubation, cells were washed twice with PBS 342 for 1 h at 37ºC and then incubated with a FITC-conjugated rabbit anti-mouse IgG antibody (Sigma- France plus 100 μgrSsEno] or PBS alone as a negative control. One week after the later 363 immunization, mice were euthanized in a CO2 chamber and bled by heart puncture to obtain serum, 364 which was aliquoted and stored at -20°C until use.
365
Quantification of the rSsEno-specific antibody response by ELISA 366 rSsEno IgG, IgG1, IgG2a and IgG3 antibody titration was conducted as described by Portuondo 367 et al. 19 with some modifications. Briefly, a 96-well ELISA plate (Costar) was coated with 5 μg
